Complementary efficacy of CD127‐directed immunotherapy with lusvertikimab and ABL‐targeting tyrosine kinase inhibitors in preclinical ABL‐class‐fusion‐positive B‐ALL
Denis Pinkle, Melissa Cornils, Anna Dietterle, Anna Laqua et autres
0 citationsHemaSphere